Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

ABSTRACT:

Background

The best management for rare epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung carcinoma (NSCLC) remains uncertain. The literature indicates that response to usual treatment could differ in certain subgroups such as exon 20 insertion/duplication (E20ID), other single uncommon mutation (OSUM), and EGFR complex mutation (ECM).

Methods

In this observational, regional, multi-center, retrospective study, we gathered data on uncommon EGFR mutations in NSCLC from 2007 to 2021. We analyzed patient characteristics, prognostic factors and treatment outcomes [objective response rate (ORR), disease control rate (DCR), progression free survival (PFS) and overall survival (OS)].

Results

Among 119 patients with an uncommon EGFR mutant, 34 h

SUBMITTER: Tankere P 

PROVIDER: S-EPMC9264085 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature